抗发作药物对第二季度产前查测试参数的影响:回顾性队列研究
Melisa Golgelioglu1, Cigdem Akcabay2, Gunes Seda Albayrak3
1Department of Obstetrics and Gynaecology, Yozgat City Hospital, 66100 Yozgat, Turkey.
Medicina (Kaunas, Lithuania)
|June 27, 2025
概括
在怀孕期间使用的抗发作药物 (ASM) 可以显著提高母体血清α-fetoprotein (AFP) 和非结合性 (uE3) 水平. 这可能导致不准确的产前查结果,需要临床医生仔细解释.
科学领域:
- 产科和妇科 产科和妇科
- 药理学 药理学是指药理学的学科.
- 医学遗传学 医学遗传学
背景情况:
- 抗发作药物 (ASM) 对于治疗孕妇至关重要.
- 人们对ASM对母体血清生物化学标志物的潜在影响存在担忧,这些标志物用于第二个三个月的产前查.
- 第二个三个月的产前查通常评估α-fetoprotein (AFP),未结合的 (uE3) 和人类胆管性腺激素 (hCG).
研究的目的:
- 评估抗发作药物 (ASM) 对母体血清AFP,UE3和hCG水平的影响.
- 为了确定ASM的使用是否会影响第二季度产前查标记的准确性.
- 评估与ASM暴露相关的胎儿先天性异常和动脉的发生率.
主要方法:
- 追溯队列研究比较了ASM的43名孕妇与43名匹配的对照.
- 倾向性得分匹配确保了基于母亲年龄,平价,BMI,吸烟状态和妊娠年龄的可比性.
- 测量了母体血清AFP,UE3和hCG水平,并在怀孕15-20周的组之间进行了比较.
主要成果:
- 与对照组相比,使用ASM的孕妇表现出明显更高的母体血清AFP和UE3水平.
- 在ASM暴露和对照组之间没有观察到hCG水平的显著差异.
- 胎儿先天性异常和动脉增生病的发病率在两组之间没有显著差异.
结论:
- 怀孕期间使用ASM显著改变了第二个三个月的母体血清生物化学标志物,特别是AFP和UE3.
- 这些变化可能导致对产前查结果的解释不准确,可能错误地分类胎儿风险.
- 在解释产前查标记时,临床医生必须考虑母亲的ASM暴露,以避免误诊和不必要的侵入性手术.
相关概念视频
01:24Epilepsy and Seizures: Overview
293
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
293
01:07Teratogenicity
2.8K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
671
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
671
01:20Antiepileptic Drugs: Potassium Channel Activators
286
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
286
01:17Antiepileptic Drugs: Calcium Channel Blockers
648
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
648
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
459
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
459